Gynecologic Oncology Reports (May 2020)

Recurrent uterine serous carcinoma with a germline pathogenic BRCA2 variant treated using olaparib: A case report

  • Kayo Inoue,
  • Hiroshi Tsubamoto,
  • Tomoko Ueda,
  • Chihiro Tajima,
  • Nami Nakagomi

Journal volume & issue
Vol. 32

Abstract

Read online

A germline pathogenic variant in BRCA2 was secondarily found through genomic sequencing of uterine serous carcinoma. Clinical response to olaparib was observed in recurrent uterine serous carcinoma with a germline BRCA2 mutation. Here, we report, for the first time, a long-term clinical response to olaparib in a patient with uterine serous carcinoma and a germline pathogenic BRCA2 variant.

Keywords